BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sahakyan Y, Lee-Kim V, Bremner KE, Bielecki JM, Krahn MD. Impact of direct-acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta-analysis. J Viral Hepat 2021;28:739-54. [PMID: 33556225 DOI: 10.1111/jvh.13482] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Cachay ER, Hadigan C, Mathews WC. Clinical guidelines for screening of liver cirrhosis complications remain, and clinical judgement must prevail. AIDS 2021;35:2211-3. [PMID: 34602589 DOI: 10.1097/QAD.0000000000003022] [Reference Citation Analysis]
2 Nakamura Y, Miyaaki H, Miuma S, Akazawa Y, Fukusima M, Sasaki R, Haraguchi M, Soyama A, Hidaka M, Eguchi S, Nakao K. Automated fibrosis phenotyping of liver tissue from non-tumor lesions of patients with and without hepatocellular carcinoma after liver transplantation for non-alcoholic fatty liver disease. Hepatol Int 2022. [PMID: 35553006 DOI: 10.1007/s12072-022-10340-9] [Reference Citation Analysis]
3 Ampuero J, Carmona I, Sousa F, Rosales JM, Lopez-Garrido A, Casado M, Figueruela B, Aparicio A, Andrade R, Guerra-Veloz MF, Maraver M, Pascasio JM, Estevez M, Romero-Gomez M. A 2-Step Strategy Combining FIB-4 With Transient Elastography and Ultrasound Predicted Liver Cancer After HCV Cure. Am J Gastroenterol 2021. [PMID: 34817975 DOI: 10.14309/ajg.0000000000001503] [Reference Citation Analysis]
4 Lockart I, Yeo MGH, Hajarizadeh B, Dore GJ, Danta M. HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis. Hepatology 2022. [PMID: 35030279 DOI: 10.1002/hep.32341] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Blach S, Blomé M, Duberg AS, Jerkeman A, Kåberg M, Klasa PE, Lagging M, Razavi-Shearer D, Razavi H, Aleman S. Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID-19. Liver Int 2021;41:2024-31. [PMID: 34051065 DOI: 10.1111/liv.14978] [Reference Citation Analysis]